{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:40:56Z","timestamp":1790804456267,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:p>Hepatocellular transporter levels were quantified using quantitative reverse transcription polymerase chain reaction and liquid chromatography\u2013tandem mass spectrometry methods. Liver function deterioration (Child\u2010Pugh class C) produced significant protein abundance (mean values) increase (to healthy livers) in P\u2010gp (to 260% (CV (coefficient of variation) 82%)) and MRP4 (CV 230%) (not detected in healthy livers), decrease in MRP2 (to 30% (CV 126%)), NTCP (to 34% (CV 112%)), OCT1 (to 35% (CV 153%)), OATP1B1 (to 46% (CV 73%)), and OATP2B1 (to 27% (CV 230%)), whereas BSEP (CV 99%), MRP3 (CV 106%), OAT2 (CV 97%), OCT3 (CV 113%), and OATP1B3 (CV 144%) remained unchanged. Alcoholic liver disease produced significant protein downregulation of MRP2 (to 30% (CV 134%)), NTCP (to 76% (CV 78%)), OAT2 (to 26% (CV 117%)), OATP1B1 (to 61% (CV 76%)), OATP1B3 (to 79% (CV 160%)), and OATP2B1 (to 73% (CV 90%)) of healthy tissue values. Hepatitis C produced BSEP (to 47% (CV 99%)) and OATP2B1 (to 74% (CV 91%)) protein reduction. Primary biliary cholangitis and primary sclerosing cholangitis demonstrated P\u2010gp and MRP4 protein upregulation (to 350% (CV 47%) and 287% (CV 38%), respectively). Autoimmune hepatitis revealed P\u2010gp (to 410% (CV 49%)) and MRP4 (CV 96%) increase, and MRP2 (to 18% (CV 259%)) protein decrease. Drug transporters' protein abundance depends on liver pathology type and its functional state.<\/jats:p>","DOI":"10.1002\/cpt.1717","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T21:55:36Z","timestamp":1573163736000},"page":"1138-1148","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Protein Abundance of Hepatic Drug Transporters in Patients With Different Forms of Liver Damage"],"prefix":"10.1111","volume":"107","author":[{"given":"Marek","family":"Drozdzik","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology Pomeranian Medical University Szczecin Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylwia","family":"Szelag\u2010Pieniek","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology Pomeranian Medical University Szczecin Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariola","family":"Post","sequence":"additional","affiliation":[{"name":"Department of General and Transplantation Surgery County Hospital Szczecin Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Zeair","sequence":"additional","affiliation":[{"name":"Department of General and Transplantation Surgery County Hospital Szczecin Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Wrzesinski","sequence":"additional","affiliation":[{"name":"Department of General and Transplantation Surgery County Hospital Szczecin Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Kurzawski","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology Pomeranian Medical University Szczecin Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Prieto","sequence":"additional","affiliation":[{"name":"Center for Applied Medical Research University of Navarra Pamplona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Oswald","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology University Medicine of Greifswald Greifswald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"e_1_2_9_1_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1183"},{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0541-7"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039060-00002"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90029-1"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127000004001207"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12470"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1734-1140(12)70888-5"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.041012"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00096-5"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.071050"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.117.077289"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1115"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2019.04.001"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1301"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1322"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2013.07.031"},{"key":"e_1_2_9_17_1","unstructured":"US Food and Drug Administration.Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design data analysis and impact on dosing and labelling<https:\/\/www.fda.gov\/media\/71311\/download> (2003)."},{"key":"e_1_2_9_18_1","unstructured":"European Medicines Agency.Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function<https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-pharmacokinetics-medicinal-products-patients-impaired-hepatic-function_en.pdf> (2005)."},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.22172"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002877"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.336"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-758-7_22"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3597(01)90074-2"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-015-0148-2"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.04.026"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.437"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02251.x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912700022008793"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.12112061"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-009-0056-4"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0740-7"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.39"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23436"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.061580"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.042259"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b00364"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.058446"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2016.06.006"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep43047"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.07.016"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.79"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2006.04.014"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109326200"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00012.2008"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.076141"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00522.2010"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14841.1"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006231-199106000-00005"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.063362"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.2165\/11318160-000000000-00000"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.1717","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1717","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.1717","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:36:44Z","timestamp":1699364204000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.1717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1002\/cpt.1717"],"URL":"https:\/\/doi.org\/10.1002\/cpt.1717","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]},"assertion":[{"value":"2019-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}